6761-52-0

Basic information

• Product Name: 3-AMINOPYRAZINE-2-CARBOHYDRAZIDE
• Synonyms: 3-AMINOPYRAZINE-2-CARBOHYDRAZIDE
• CAS NO: 6761-52-0
• Molecular Formula: C₅H₇N₅O
• Molecular Weight: 153.14
• Mol File: 6761-52-0.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 3-AMINOPYRAZINE-2-CARBOHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINOPYRAZINE-2-CARBOHYDRAZIDE(6761-52-0)
• EPA Substance Registry System: 3-AMINOPYRAZINE-2-CARBOHYDRAZIDE(6761-52-0)

Safety Data

• Hazardous Substances Data: 6761-52-0(Hazardous Substances Data)

Usage

General Description

3-Aminopyrazine-2-carbohydrazide is a chemical compound with the molecular formula C4H7N5O. It is a white to off-white solid that is soluble in water and organic solvents. 3-AMINOPYRAZINE-2-CARBOHYDRAZIDE is used as a reagent in organic synthesis, particularly in the preparation of pharmaceuticals and agrochemicals. It can also be used as a catalyst in the production of polymers and as a precursor to other organic compounds. Additionally, 3-aminopyrazine-2-carbohydrazide has shown potential as an inhibitor of certain enzymes, making it a valuable tool in biochemical research. Overall, this compound has a wide range of applications in various industries due to its versatile chemical properties.

Upstream product

• 32587-10-3 3-aminopyrazine-2-carboxamide 
• 16298-03-6 Methyl 3-amino-2-pyrazinecarboxylate 
• 5424-01-1 3-aminopyrazinoic acid 

Downstream Products

• 114953-93-4 3-(5-Phenyl-1H-[1,2,4]triazol-3-yl)-pyrazin-2-ylamine 
• 1402083-96-8 2-(5-(3-amino-pyrazin-2-yl)-1,3,4-oxadiazol-2-ylthio)-1-(4-phenylpiperazin-1-yl)ethanone 
• 1402083-77-5 2-(3-amino-pyrazine-2-carbonyl)-N-benzylhydrazinecarbothiamide 
• 1402083-79-7 2-(3-amino-pyrazine-2-carbonyl)-N-(4-bromophenyl)hydrazinecarbothioamide 
• 1402083-80-0 2-(3-amino-pyrazine-2-carbonyl)-N-(4-chlorophenyl)hydrazinecarbothioamide 
• 681136-57-2 3-amino-N'-(4-chlorobenzylidene)pyrazine-2-carbohydrazide 
• 1402083-86-6 3-amino-N'-(3,4,5-trimethoxybenzylidene)pyrazine-2-carbohydrazide 
• 1402083-87-7 3-amino-N'-(1-phenylethylidene)pyrazine-2-carbohydrazide 
• 1402083-88-8 3-amino-N'-(1-(4-chlorophenyl)ethylidene)pyrazine-2-carbohydrazide 
• 1402083-89-9 3-amino-N'-cyclohexylidenepyrazine-2-carbohydrazide 
• 1620576-86-4 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1H-1,2,4-triazol-3-yl)piperidin-1-yl)-3-(tetrahydro-2H-pyran-2-yloxy)propan-1-one 
• 1620576-64-8 AZD-8835 

Relevant articles and documents

Recursive partitioning analysis and anti-tubercular screening of 3- aminopyrazine-2-carbohydrazide derivatives

Background: Treating tuberculosis is a challenge due to the development of drug resistance. Hence, it is imperative to develop novel leads having high potency and efficacy to curb drug resistance. Methods: The present research work is focused on microwave

Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers

Starting from potent inhibitors of PI3Kα having poor general kinase selectivity (e.g., 1 and 2), optimisation of this series led to the identification of 25, a potent inhibitor of PI3Kα (wild type, E545K and H1047R mutations) and PI3Kδ, selective versus PI3Kβ and PI3Kγ, with excellent general kinase selectivity. Compound 25 displayed low metabolic turnover and suitable physical properties for oral administration. In vivo, compound 25 showed pharmacodynamic modulation of AKT phosphorylation and near complete inhibition of tumour growth (93% tumour growth inhibition) in a murine H1047R PI3Kα mutated SKOV-3 xenograft tumour model after chronic oral administration at 25 mg/kg b.i.d. Compound 25, also known as AZD8835, is currently in phase I clinical trials.

CHEMICAL COMPOUNDS

The invention concerns compounds of Formula (I) (Formula (I)) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined herein before in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.